Perpetual Ltd Acquires Shares of 827,217 Genmab A/S Sponsored ADR $GMAB

Perpetual Ltd bought a new position in Genmab A/S Sponsored ADR (NASDAQ:GMAB) in the 4th quarter, Holdings Channel.com reports. The firm bought 827,217 shares of the company’s stock, valued at approximately $25,478,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Federated Hermes Inc. acquired a new stake in Genmab A/S in the third quarter valued at about $12,972,000. Oppenheimer Asset Management Inc. increased its position in Genmab A/S by 24.1% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 315,862 shares of the company’s stock worth $9,687,000 after purchasing an additional 61,311 shares during the period. JPMorgan Chase & Co. increased its position in Genmab A/S by 17.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 933,309 shares of the company’s stock worth $19,282,000 after purchasing an additional 135,814 shares during the period. Eagle Global Advisors LLC raised its stake in shares of Genmab A/S by 16.3% during the 3rd quarter. Eagle Global Advisors LLC now owns 244,470 shares of the company’s stock worth $7,498,000 after buying an additional 34,175 shares in the last quarter. Finally, Squarepoint Ops LLC raised its stake in shares of Genmab A/S by 636.3% during the 2nd quarter. Squarepoint Ops LLC now owns 94,233 shares of the company’s stock worth $1,947,000 after buying an additional 81,434 shares in the last quarter. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on the company. Jefferies Financial Group began coverage on Genmab A/S in a research note on Tuesday, February 17th. They issued a “buy” rating and a $41.50 price target on the stock. Morgan Stanley began coverage on Genmab A/S in a research report on Monday, February 16th. They issued an “equal weight” rating and a $34.00 price objective for the company. Guggenheim reduced their target price on Genmab A/S from $45.00 to $40.00 and set a “buy” rating for the company in a report on Monday, February 23rd. Truist Financial upgraded shares of Genmab A/S to a “strong-buy” rating in a research report on Wednesday, March 25th. Finally, Wall Street Zen cut shares of Genmab A/S from a “buy” rating to a “hold” rating in a research note on Saturday, February 7th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, Genmab A/S currently has a consensus rating of “Moderate Buy” and an average price target of $39.36.

Genmab A/S Price Performance

Shares of NASDAQ:GMAB opened at $27.50 on Friday. The firm has a market capitalization of $17.67 billion, a price-to-earnings ratio of 17.74, a price-to-earnings-growth ratio of 1.24 and a beta of 0.97. The company has a debt-to-equity ratio of 0.86, a current ratio of 2.02 and a quick ratio of 2.01. The business’s 50 day simple moving average is $28.83 and its 200-day simple moving average is $30.42. Genmab A/S Sponsored ADR has a 12 month low of $17.24 and a 12 month high of $35.43.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings data on Tuesday, February 17th. The company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.46 by ($0.41). The firm had revenue of $1.06 billion during the quarter, compared to analysts’ expectations of $1.06 billion. Genmab A/S had a net margin of 25.89% and a return on equity of 17.35%. As a group, equities analysts forecast that Genmab A/S Sponsored ADR will post 1.45 earnings per share for the current fiscal year.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.